Fundz

ABIONYX Pharma received €8.7 million in a grant from the French government to combat Sepsis through their innovative project.

PRIVATEFeb 20, 2025

Amount Raised

€8.7 Million

Round Type

Grant

BalmaBiotechnology

Description

ABIONYX Pharma has been awarded €8.7 million from the French government as part of the France 2030 Plan’s 'i-Démo' call for projects to advance their CER-001 Sepsis project. This funding will support their development of innovative therapies using the natural recombinant apoA-I protein.

Quick answer

ABIONYX Pharma raised €8.7 Million in a Grant round, dated February 20, 2025. ABIONYX Pharma is based in Balma, Occitanie, France.

How much did ABIONYX Pharma raise?
ABIONYX Pharma raised €8.7 Million in a Grant round on February 20, 2025.
What does ABIONYX Pharma do?
ABIONYX Pharma is a new generation biotech company dedicated to the discovery and development of innovative therapies for patients without existing or effective treatment.
Where is ABIONYX Pharma based and how big is it?
ABIONYX Pharma is based in Balma, Occitanie, France. Fundz records about 8 employees.
Who are the decision-makers at ABIONYX Pharma?
Fundz holds 1 contact at ABIONYX Pharma. Names and contact details are shown to Fundz members.

Source: Fundz verified event record.

Who else raised in Biotechnology around the same time

Companies in the same sectors as ABIONYX Pharma that raised within 45 days of this round, from Fundz verified event records.

  • Treysta Medical Technologies raised $93K (Pre-Seed) on April 4, 2025.
  • Astek Diagnostics raised $750K (Series A) on April 4, 2025.
  • Exobiosphere raised $2.2M (Seed) on April 4, 2025.
  • RayThera raised $110M (Series A) on April 4, 2025.
  • FOXO Technologies raised $325K (Seed) on April 4, 2025.
  • Perkant Tech raised $772K (Seed) on April 3, 2025.

Who to call at ABIONYX Pharma, and when

A new round usually means ABIONYX Pharma is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day ABIONYX Pharma raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at ABIONYX Pharma, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at ABIONYX Pharma. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

ABIONYX Pharma

Location

Balma, Occitanie, France

About

ABIONYX Pharma is a new generation biotech company dedicated to the discovery and development of innovative therapies for patients without existing or effective treatment.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment ABIONYX Pharma raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Predictive Intelligence
Strategic

ML-powered predictions for ABIONYX Pharma's next move

See what Strategic adds

ABIONYX Pharma raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.